FDA Approves New Subcutaneous Treatment for Crohn's Disease

The U.S. FDA has approved a subcutaneous induction regimen of risankizumab (Skyrizi, AbbVie) for adults with moderately to severely active Crohn's disease. This provides an additional treatment option for patients managing this chronic inflammatory bowel condition.